製品名:(R)-Oxiran-2-ylmethyl 3-nitrobenzenesulfonate

IUPAC Name:[(2R)-oxiran-2-yl]methyl 3-nitrobenzene-1-sulfonate

CAS番号:115314-17-5
分子式:C9H9NO6S
純度:95%+
カタログ番号:CM247886
分子量:259.23

包装単位 有効在庫 価格(USD) 数量
CM247886-25g in stock ƴȅ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:115314-17-5
分子式:C9H9NO6S
融点:-
SMILESコード:O=S(C1=CC=CC([N+]([O-])=O)=C1)(OC[C@@H]2OC2)=O
密度:
カタログ番号:CM247886
分子量:259.23
沸点:432.2°C at 760 mmHg
MDL番号:MFCD00013436
保管方法:Keep in inert atmosphere, store at 2-8°C.

Category Infos

Oxiranes
Oxirane is a three-membered ring compound consisting of one oxygen atom and two carbon atoms. Oxirane is present in natural products such as cryptocin, which has anticancer properties, and azidomycin, trienone, and epoxidomycin, which have shown activity against drug-resistant leukemias and AIDS-related lymphomas. Other oxirane containing bioactive molecules have anti-inflammatory, immunosuppressive, and antitumor activities. Oxiranes are a strained ring susceptible to various nucleophilic, ring-opening or rearrangement reactions, so they are considered to be one of the most important intermediates in organic synthesis.

Column Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Encaleret
New England Journal of Medicine(NEJM) publication of positive encaleret proof-of-concept phase 2b results in patients with autosomal dominant hypocalcemia type 1 (ADH1).
Encaleret is an investigational, orally administered small molecule that selectively antagonizes the calcium sensing receptor (CaSR), targeting ADH1 at its source. If approved, encaleret could be the first therapy specifically indicated for the treatment of ADH1.
Encaleret has received fast track designation by the U.S. FDA and orphan drug designation in the United States and the European Union.

Related Products